Overview

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Status:
Completed

Trial end date:
2021-05-14

Target enrollment:

Participant gender:

Summary

To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Rhizen Pharmaceuticals SA

Treatments:

Histone Deacetylase Inhibitors
Romidepsin
Tenalisib